The internalization and degradation of human copper transporter 1 following cisplatin exposure

Cancer Research

Volumn 66, Issue 22, 2006, Pages 10944-10952

  Holzer, Alison K ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CARRIER PROTEIN; CISPLATIN; CYTOCHALASIN D; DYNAMIN I; LACTACYSTIN; METHYL BETA CYCLODEXTRIN; NYSTATIN; PROTEIN COPPER TRANSPORTER 1; RAC PROTEIN;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INHIBITION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; WESTERN BLOTTING;

AMILORIDE; BETA-CYCLODEXTRINS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CISPLATIN; CYTOCHALASIN D; FEMALE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, CONFOCAL; NYSTATIN; OVARIAN NEOPLASMS; PINOCYTOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 33845317647     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1710     Document Type: Article

References (37)

1. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001;59:657-63.
2. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cell 1990;2:35-43.
3. Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-diamminedichloroplatinum(ii) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 1990;2:93-100.
4. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993;67:1171-6.
5. Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005;53:13-23.
6. Pena MM, Lee J, Thiele DJ. A delicate balance: homeostatic control of copper uptake and distribution. J Nutr 1999;129:1251-60.
7. Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62:6559-65.
8. Safaei R, Katano K, Samimi G, et al. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 2004;53:239-46.
9. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002;62:1154-9.
10. Holzer AK, Samimi G, Katano K, et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 2004;66:817-23.
11. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002;99:14298-302.
12. Song IS, Savaraj N, Siddik ZH, et al. Roles of copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and resistant cells. Mol Cancer Ther 2004;3:1543-9.
13. Petris MJ. The SLC31 (Ctr) copper transporter family. Pflugers Arch 2004;447:752-5.
14. Petris MJ, Smith K, Lee J, Thiele DJ. Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem 2003;278:9639-46.
15. Ooi CE, Rabinovich E, Dancis A, Bonifacino JS, Klausner RD. Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. EMBO J 1996;15:3515-23.
16. Holzer AK, Katano K, Klomp LW, Howell SB. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 2004;10:6744-9.
17. Klomp AE, Tops BB, Van Denberg IE, Berger R, Klomp LW. Biochemical characterization and subcellular localization of human copper transporter 1 (hCTR1). Biochem J 2002;364:497-505.
18. Hamilton TC, Winker MA, Louie KG, et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity by buthionine sulfoximine depletion of glutathione in drug resistant human ovarian cancer. Proc Am Assoc Cancer Res 1985;26:345-7.
19. Disaia PJ, Sinkovics JG, Rutledge FN, Smith JP. Cell-mediated immunity to human malignant cells. Am J Obstet Gynecol 1972;114:979-89.
20. Damke H, Baba T, Warnock DE, Schmid SL. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol 1994;127:915-34.
21. Araki N, Johnson MT, Swanson JA. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J Cell Biol 1996;135:1249-60.
22. Oliver JM, Berlin RD, Davis BH. Use of horseradish peroxidase and fluorescent dextrans to study fluid pinocytosis in leukocytes. Methods Enzymol 1984;108:336-47.
23. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003;422:37-44.
24. Riezman H, Woodman PG, van Meer G, Marsh M. Molecular mechanisms of endocytosis. Cell 1997;91:731-8.
25. Rodal SK, Skretting G, Garred O, Vilhardt F, van Deurs B, Sandvig K. Extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell 1999;10:961-74.
26. Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE. Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci U S A 1999;96:6775-80.
27. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004;116:167-79.
28. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-10.
29. Peters C, von Figura K. Biogenesis of lysosomal membranes. FEBS Lett 1994;346:108-14.
30. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002;25:289-303.
31. Johannes L, Lamaze C. Clathrin-dependent or not: is it still the question? Traffic 2002;3:443-51.
32. Nichols BJ, Lippincott-Schwartz J. Endocytosis without clathrin coats. Trends Cell Biol 2001;11:406-12.
33. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10:310-5.
34. Guo Y, Smith K, Petris MJ. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters. J Biol Chem 2004;279:46393-9.
35. Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 2005;55:55-60.
36. Filipski J, Kohn KW, Bonner WM. Differential cross-linking of histones and non-histones in nuclei by cis-Pt(ii). FEBS Lett 1983;152:105-8.
37. Holzer AK, Manorek GH, Howell SB. The role of the copper transport protein 1 in the cellular accumulation of cisplatin, oxaliplatin, and carboplatin. Proc Am Assoc Cancer Res 2006;47:311.